Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17476930 | 0.86 | PDE4B (0.36) | PDE4BPDE4DABHD6LMNAMAPK1 | |
| SCHEMBL17476953 | 0.75 | PDE4B (0.40) | PDE4BPDE4D | |
| SCHEMBL16179749 | 0.69 | PDE4B (0.41) | PDE4BPDE4DLMNAMAPK1HTT | |
| SCHEMBL17476929 | 0.66 | PDE4B (0.38) | PDE4BPDE4DLMNAMAPK1HTT | |
| SCHEMBL16446805 | 0.65 | PDE4B (0.44) | PDE4BPDE4DLMNAMAPK1HTT | |
| SCHEMBL19118422 | 0.65 | RAB9A (0.43) | PDE4BPDE4DLMNAMAPK1HTT | |
| SCHEMBL16446133 | 0.64 | GAA (0.51) | PDE4BPDE4DLMNAMAPK1HTT | |
| SCHEMBL15924860 | 0.63 | PDE4B (0.53) | PDE4BPDE4DLMNAMAPK1HTT | |
| SCHEMBL16447032 | 0.63 | DCTPP1 (0.47) | PDE4BPDE4DLMNAMAPK1HTT | |
| SCHEMBL6075610 | 0.62 | MAPK1 (0.52) | PDE4BPDE4DLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986600-B1 | SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-9527832-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2016-12-27 | — | — | US | disclosed |
| US-20160031857-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031857-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | TYMP, PDE4A, DPYD | PDE4B 4/4885PDE4D 8/4885ABHD6 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.